Free Trial

Daxor (DXR) Competitors

Daxor logo
$7.76 +0.16 (+2.11%)
As of 03:18 PM Eastern

DXR vs. PDEX, LUNG, ZJYL, PROF, LUCD, INFU, OBIO, ICAD, MGRM, and GUTS

Should you be buying Daxor stock or one of its competitors? The main competitors of Daxor include Pro-Dex (PDEX), Pulmonx (LUNG), Jin Medical International (ZJYL), Profound Medical (PROF), Lucid Diagnostics (LUCD), InfuSystem (INFU), Orchestra BioMed (OBIO), iCAD (ICAD), Monogram Orthopaedics (MGRM), and Fractyl Health (GUTS). These companies are all part of the "medical equipment" industry.

Daxor vs.

Daxor (NASDAQ:DXR) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.

Daxor has a beta of -0.21, meaning that its share price is 121% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500.

1.3% of Daxor shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 59.0% of Daxor shares are owned by company insiders. Comparatively, 47.5% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pro-Dex has a net margin of 11.06% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 21.68% beat Daxor's return on equity.

Company Net Margins Return on Equity Return on Assets
DaxorN/A N/A N/A
Pro-Dex 11.06%21.68%12.40%

Pro-Dex received 154 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 61.90% of users gave Pro-Dex an outperform vote.

CompanyUnderperformOutperform
DaxorOutperform Votes
2
100.00%
Underperform Votes
No Votes
Pro-DexOutperform Votes
156
61.90%
Underperform Votes
96
38.10%

Pro-Dex has higher revenue and earnings than Daxor.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Daxor$2.13M17.25N/AN/AN/A
Pro-Dex$64.12M2.31$2.13M$2.8016.22

In the previous week, Pro-Dex had 2 more articles in the media than Daxor. MarketBeat recorded 2 mentions for Pro-Dex and 0 mentions for Daxor. Pro-Dex's average media sentiment score of 1.42 beat Daxor's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media.

Company Overall Sentiment
Daxor Neutral
Pro-Dex Positive

Daxor currently has a consensus target price of $25.00, indicating a potential upside of 228.95%. Pro-Dex has a consensus target price of $52.00, indicating a potential upside of 14.47%. Given Daxor's higher probable upside, analysts plainly believe Daxor is more favorable than Pro-Dex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Daxor
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Pro-Dex
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Pro-Dex beats Daxor on 9 of the 13 factors compared between the two stocks.

Get Daxor News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXR vs. The Competition

MetricDaxorSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$36.76M$4.53B$5.40B$8.49B
Dividend YieldN/A43.65%5.22%4.11%
P/E RatioN/A29.8226.7119.93
Price / Sales17.2570.77395.44119.84
Price / CashN/A51.0838.2534.62
Price / BookN/A6.316.854.59
Net IncomeN/A$68.16M$3.23B$248.19M
7 Day Performance4.11%21.03%5.35%2.21%
1 Month Performance-4.76%25.54%13.31%16.23%
1 Year Performance-21.49%22.21%17.58%8.00%

Daxor Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXR
Daxor
3.8598 of 5 stars
$7.76
+2.1%
$25.00
+222.2%
-21.5%$37.54M$2.13M0.0037
PDEX
Pro-Dex
2.6471 of 5 stars
$42.49
+5.5%
$52.00
+22.4%
+130.9%$138.56M$64.12M21.14140News Coverage
Positive News
High Trading Volume
LUNG
Pulmonx
3.5245 of 5 stars
$3.32
-9.8%
$12.07
+263.6%
-62.4%$133.66M$87.47M-2.31250Positive News
ZJYL
Jin Medical International
N/A$0.85
-5.7%
N/A-74.2%$132.60M$23.50M0.00245
PROF
Profound Medical
2.3139 of 5 stars
$4.27
-0.2%
$11.50
+169.3%
-39.2%$128.33M$10.68M-3.19150
LUCD
Lucid Diagnostics
3.0297 of 5 stars
$1.19
+8.2%
$3.50
+194.1%
+39.8%$125.41M$4.35M-1.0470High Trading Volume
INFU
InfuSystem
2.4633 of 5 stars
$5.75
+4.9%
$13.00
+126.1%
N/A$120.84M$134.86M95.85410News Coverage
Positive News
High Trading Volume
OBIO
Orchestra BioMed
2.8577 of 5 stars
$2.94
+10.9%
$14.20
+383.0%
-43.6%$112.64M$2.64M-1.834
ICAD
iCAD
0.4759 of 5 stars
$3.93
+5.9%
N/A+141.5%$107.86M$19.61M-30.23140News Coverage
Analyst Forecast
High Trading Volume
MGRM
Monogram Orthopaedics
3.266 of 5 stars
$2.59
-1.5%
$5.40
+108.5%
+40.1%$91.40M$364,999.00-5.5128Earnings Report
GUTS
Fractyl Health
1.7382 of 5 stars
$1.77
+3.5%
$11.00
+521.5%
-69.9%$86.69M$93,000.00-0.15102

Related Companies and Tools


This page (NASDAQ:DXR) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners